BIOMAT Database Logo BIOMAT Database Logo

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. 1993

R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

In vitro evaluation of a large chemical library of pharmacologically acceptable prototype compounds in a high-capacity, cellular-based screening system has led to the discovery of another family of human immunodeficiency virus type 1 (HIV-1) inhibitors. Through optimization of a lead compound, several alpha-anilinophenylacetamide (alpha-APA) derivatives have been identified that inhibit the replication of several HIV-1 strains (IIIB/LAI, RF, NDK, MN, HE) in a variety of host cell types at concentrations that are 10,000- to 100,000-fold lower than their cytotoxic concentrations. The IC50 of the alpha-APA derivative R 89439 for HIV-1 cytopathicity in MT-4 cells was 13 nM. The median 90% inhibitory concentration (IC90) in a variety of host cells was 50-100 nM. Although these alpha-APA derivatives are active against a tetrahydroimidazo [4,5,1-jk][1,4]benzodiazepin-2(1H)-thione-(TIBO)-resistant HIV-1 strain, they do not inhibit replication of HIV-2 (strains ROD and EHO) or simian immunodeficiency virus (strains Mac251, mndGB1, and agm3). An HIV-1 strain containing the Tyr181-->Cys mutation in the reverse transcriptase region displayed reduced sensitivity. alpha-APA derivative R 89439 inhibited virion and recombinant reverse transcriptase of HIV-1 but did not inhibit that of HIV-2. Reverse transcriptase inhibition depended upon the template/primer used. The relatively uncomplicated synthesis of R 89439, its potent anti-HIV-1 activity, and its favorable pharmacokinetic profile make R 89439 a good candidate for clinical studies.

UI MeSH Term Description Entries
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D000098 Acetophenones Derivatives of the simplest aromatic ketone acetophenone (of general formula C6H5C(O)CH3).
D000814 Aniline Compounds Compounds that include the aminobenzene structure. Phenylamine,Phenylamines,Anilines,Compounds, Aniline
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015302 Simian Immunodeficiency Virus Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV. SIV (Simian immunodeficiency virus),Immunodeficiency Viruses, Simian,Simian Immunodeficiency Viruses,Immunodeficiency Virus, Simian
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669

Related Publications

R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
May 1995, Journal of medicinal chemistry,
R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.
March 1991, Proceedings of the National Academy of Sciences of the United States of America,
R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives.
June 1991, Molecular pharmacology,
R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
May 1993, Medicinal research reviews,
R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase.
May 1996, Antiviral research,
R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives.
August 1990, FEBS letters,
R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors.
November 1995, Journal of medicinal chemistry,
R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives.
June 1997, Antimicrobial agents and chemotherapy,
R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
Thiadiazole derivatives: highly potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replications in vitro.
January 1997, Microbiology and immunology,
R Pauwels, and K Andries, and Z Debyser, and P Van Daele, and D Schols, and P Stoffels, and K De Vreese, and R Woestenborghs, and A M Vandamme, and C G Janssen
Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles.
April 2013, Nanoscale,
Copied contents to your clipboard!